InsidersTradesSigma
Quantum-Si Inc Stock: price and directors' dealings · United States · SEC (Form 4)
Track the Quantum-Si Inc stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Quantum-Si Inc has recorded 71 reports. The latest transaction was disclosed on 24 June 2026 (Cession). Among the most active insiders: LaPointe Christian. The full history is free.
71
Insider Decl.
0
Thresholds
€506,164
10 ops.
Buy Volume
€5m
23 ops.
Sell Volume
49Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 24 June 2026
Declarations71 total
7,794 sharesClass A Common StockSEC:0001140361-26-026294:0
7,794 sharesClass A Common StockSEC:0001140361-26-026294:1
11,310 sharesClass A Common StockSEC:0001140361-26-026285:0
11,311 sharesClass A Common StockSEC:0001140361-26-026285:1
4,116 sharesClass A Common StockSEC:0001140361-26-026290:0
4,117 sharesClass A Common StockSEC:0001140361-26-026290:1
23,707 shares@ US$1.385533.7% of flowClass A Common StockSEC:0001140361-25-010084:0
4,317 shares@ US$1.385543.3% of flowClass A Common StockSEC:0001140361-25-010074:0
8,626 shares@ US$1.38558.8% of flowClass A Common StockSEC:0001140361-25-010078:0
4,896 shares@ US$1.38552.3% of flowClass A Common StockSEC:0001140361-25-010082:0
750,000 shares0Class A Common StockSEC:0001140361-25-008851:0
708,333 shares0Class A Common StockSEC:0001140361-25-008849:0
1,666,666 shares0Class A Common StockSEC:0001140361-25-008848:0
416,666 shares0Class A Common StockSEC:0001140361-25-008852:0
208,333 shares0Class A Common StockSEC:0001140361-25-008850:0
834,253 shares@ US$3.303497.2% of flowClass A Common StockSEC:0001140361-24-050719:0
4,306 shares@ US$1.293642.0% of flowClass A Common StockSEC:0001140361-24-050424:0
2,192 shares@ US$0.945914.7% of flowClass A Common StockSEC:0001140361-24-041897:0
510,152 shares0Class A Common StockSEC:0001140361-24-041377:0
138,900 shares@ US$0.8706100.0% of flowClass A Common StockSEC:0001140361-24-036919:0
Ideal exit: 6 May 2025 (T+270)
25,000 shares@ US$0.86447.1% of flowClass A Common StockSEC:0001140361-24-036921:0
Ideal exit: 6 May 2025 (T+270)
50,000 shares@ US$0.869331.9% of flowClass A Common StockSEC:0001140361-24-036920:0
Ideal exit: 6 May 2025 (T+270)
25,000 shares@ US$0.850921.7% of flowClass A Common StockSEC:0001140361-24-036922:0
Ideal exit: 6 May 2025 (T+270)
4,359 shares@ US$1.2072100.0% of flowClass A Common StockSEC:0001140361-24-031348:0
159,217 shares0Class A Common StockSEC:0001140361-24-015042:0
25 of 71 declarations
About Quantum-Si Inc
Quantum-Si Inc. is a U.S.-based healthcare technology company listed on the Nasdaq under the ticker QSI, with warrants trading as QSIAW. Headquartered in Branford, Connecticut, United States, the company was founded in 2013 around a disruptive thesis: applying semiconductor and electronics design principles to protein analysis in order to make proteomics more accessible, faster, and more informative for research laboratories. Following its 2021 business combination with HighCape Capital Acquisition Corp., Quantum-Si gained public-market visibility and established itself as a specialized player in next-generation proteomics. Quantum-Si’s business model centers on a proprietary single-molecule detection platform applied to protein sequencing. The company currently markets its Platinum product line, which includes benchtop instruments and associated consumable kits for academic, pharmaceutical, and translational research customers. Its offering is designed to move beyond traditional proteomics workflows, which are often labor-intensive and multistep, by providing high-resolution functional and dynamic protein insights. Strategically, Quantum-Si is working to simplify proteomics workflows and build an installed base that can support recurring revenue from consumables and kits. From a competitive standpoint, Quantum-Si operates in an emerging market and faces indirect competition from established players in sequencing, mass spectrometry, and broader multi-omics platforms. Its differentiation lies in a hardware-led approach built on semiconductor chips and monomolecular protein detection. That positioning may prove attractive if the platform continues to validate technically and commercially, but it remains early in the commercialization curve. The company’s customer base is primarily global scientific and research organizations, with commercial exposure centered on the United States and other advanced research markets through direct sales, partnerships, and distribution relationships. Recent milestones suggest continued platform development and commercialization efforts. In 2024 and 2025, Quantum-Si highlighted progress on Proteus, a next-generation hardware platform expected to reach commercial launch later in the product cycle. The company has also continued to expand its sequencing kit portfolio and pursue collaborations aimed at improving proteomics data utility. Recent press releases and SEC filings indicate management remains focused on product performance, adoption, and industrialization. For French-speaking investors, Quantum-Si remains a high-risk growth story with typical exposure to adoption risk, financing needs, dilution potential, and an uncertain path to sustained profitability.
